Table 4 Evaluation of epidemiological and clinical variables according to IgG persistence 90 days after diagnosis
From: Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
Variables | 2nd IgG test | p | ||
|---|---|---|---|---|
N | Persistent n = 87 n (%) | Nonpersistent n = 38 n (%) | ||
Sex | ||||
Female | 83 | 56 (64.0) | 27 (70.5) | 0.6017* |
Male | 42 | 31 (36.0) | 11 (29.5) | |
Age | ||||
< 60 years old | 94 | 61 (73.3) | 33 (85.3) | 0.0773* |
≥ 60 years old | 31 | 26 (26.7) | 5 (14.7) | |
Symptoms | ||||
Yes | 123 | 87 (100) | 36 (94.1) | 0.1902** |
No | 02 | 0 | 2 (5.9) | |
Duration of symptoms | ||||
≤ 7 days | 40 | 24 (26.7) | 16 (50.0) | 0.1424* |
15 days | 39 | 28 (33.7) | 11 (29.4) | |
≥ 21 days | 44 | 35 (39.6) | 9 (20.6) | |
Hospitalization | ||||
Yes | 11 | 10 (10.5) | 1 (2.9) | 0.1756* |
No | 114 | 77 (89.5) | 37 (97.1) | |
Supplemental oxygen | ||||
Yes | 11 | 10 (10.5) | 1 (2.9) | 0.1756** |
No | 114 | 77 (89.5) | 37 (97.1) | |
H1N1 vaccine | ||||
Yes | 106 | 71 (81.4) | 35 (91.2) | 0.1997** |
No | 19 | 16 (18.6) | 3 (8.8) | |
BCG vaccine | ||||
Yes | 102 | 71 (88.4) | 31 (79.4) | 0. 6766** |
No | 09 | 5 (5.8) | 4 (11.8) | |
Unknown | 08 | 5 (5.8) | 3 (8.8) | |